Form 4: Ultragenyx Pharmaceutical Inc. Executive John Richard Pinion Reports Stock Transactions

John Richard Pinion, an officer at Ultragenyx Pharmaceutical Inc., reports acquisition and disposal of company stock and derivative securities.

Summary

• On March 1, 2025, John Richard Pinion acquired 14,494 shares of common stock through Restricted Stock Units (RSUs) and 18,443 shares through the conversion of performance stock units, both at $0.
• Also on March 1, 2025, Pinion was granted an option to buy 26,074 shares of common stock at an exercise price of $42.92, vesting over four years.
• On March 3, 2025, Pinion sold 14,439 shares at an average price of $42.1 to cover tax withholdings related to the vesting of RSUs.
• Additionally, on March 3, 2025, 31 shares were surrendered to the issuer to cover tax withholdings at a price of $42.92.
• Following these transactions, Pinion beneficially owns 107,766 shares of common stock and holds options for 26,074 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing primarily reports routine transactions related to equity compensation. There are no explicit positive or negative indicators, but the granting of equity can be seen as a positive incentive.

Positives

• The granting of stock options and RSUs to an officer can be seen as a positive incentive aligning the officer's interests with those of the shareholders.

Negatives

• The sale of shares to cover tax withholdings could be interpreted as a need for immediate liquidity, although it's a common practice.

Risks

• The vesting schedule of the RSUs and stock options means that the officer's continued employment and performance are tied to the value of the stock over the long term.
• Market fluctuations could impact the value of the shares and options, affecting the officer's compensation and incentives.

Future Outlook

The vesting schedule of the RSUs and stock options indicates a long-term incentive structure for the reporting person.

Industry Context

Form 4 filings are standard practice for reporting insider transactions, providing transparency to investors regarding the buying and selling activities of company executives and directors. This filing indicates routine transactions related to equity compensation.

Comparison to Industry Standards

• Equity compensation is a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.
• Vesting schedules and tax withholding practices are generally standardized across companies.
• Comparing the size of the equity grants and sales to those of executives at comparable pharmaceutical companies (e.g., Amgen, Gilead Sciences) would provide further context.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding insider activity.
• The equity compensation structure incentivizes the officer to contribute to the company's long-term success.

Key Dates